Business
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeu
About this update from Beyondspring, Inc.
[{"type":"image","alt":"BeyondSpring, Inc.","displaySize":"","headline":null,"caption":"BeyondSpring, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":255,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iztnDk_H5MGcKZO6_GJ5Qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766","width":255,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. Docetaxel","length":168,"tagName":"p"}]},{"val":[{"type":"text","content":"Plinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLC","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"SEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 Financing","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"SEED Therapeutics’ Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA","length":124,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":621,"olType":false},{"type":"text","content":"FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced its financial results for the year ended December 31, 2024, and provided a business update on key clinical and corporate developments.","length":363,"tagName":"p"},{"type":"text","content":"“2024 was a pivotal year for BeyondSpring, with significant clinical progress for our first-in-class agent Plinabulin and strategic advancements for SEED Therapeutics (SEED), which BeyondSpring co-founded and owns an equity stake in. We believe these developments create value benefiting all stakeholders,” said Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring.","length":383,"tagName":"p"},{"type":"text","content":"“Plinabulin ...